Early Retinal Neurodegeneration As Risk Factor, Biomarker and Pharmacological Target of Diabetic Retinopathy
Recruiting
Observational Study
Diabetic Retinopathy
Diabetic Retinopathy Associated with Type 2 Diabetes Mellitus
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Healthy Volunteers Welcome
You do not need to have the condition being studied to take part.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 40 – 80
- Sex
- Any
- Study type
- Observational
- Participants needed
- 180 (estimated)
- Sponsor
- IRCCS Ospedale San Raffaele · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Despite the evidence that diabetic retinopathy (DR) remains the first cause of blindness among the working-age population, it lacks a specific preventive treatment. This is because early mechanisms leading to the development of DR have been, until recently, unknown. Recent studies have suggested that the early stages of DR could be preceded by neuronal abnormalities, in particular retinal ganglion…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria - Longitudinal study (patients):
1. Participant is willing and able to give informed consent for participation in the trial.
2. Male or Female, aged 40 - 80 years;
3. In good general health as evidenced by medical history or diagnosed with type 2 diabetes for less than 10 years w…
Contacts
No contact information available.